About Sarepta Therapeutics (NASDAQ:AVII)
Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD). It is focused on the development of its disease-modifying DMD drug candidates. It has received accelerated approval for its product, EXONDYS 51, indicated for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping. EXONDYS 51 is studied in clinical trials under the name of eteplirsen. Its next generation phosphorodiamidate morpholino oligomer (PMO)-based compounds are synthetic compounds that bind to complementary sequences of RNA by standard Watson-Crick nucleobase pairing. Its PMO-based chemistries are peptide conjugated PMO (PPMO), PMO-X and PMOplus.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:AVII
- CUSIP: N/A
- Web: https://www.sarepta.com/
- Trailing P/E Ratio: N/A
- P/E Growth: N/A
- Net Margins: -180.07%
- Return on Equity: -62.68%
- Return on Assets: -52.59%
Frequently Asked Questions for Sarepta Therapeutics (NASDAQ:AVII)
What is Sarepta Therapeutics' stock symbol?
Sarepta Therapeutics trades on the NASDAQ under the ticker symbol "AVII."
Who are some of Sarepta Therapeutics' key competitors?
Some companies that are related to Sarepta Therapeutics include Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals Incorporated (VRTX), Kite Pharma (KITE), Exelixis (EXEL), Bioverativ (BIVV), bluebird bio (BLUE), TESARO (TSRO), Neurocrine Biosciences (NBIX), Juno Therapeutics (JUNO), Clovis Oncology (CLVS), BeiGene (BGNE), Sarepta Therapeutics (SRPT), Agios Pharmaceuticals (AGIO), AveXis (AVXS), GW Pharmaceuticals PLC (GWPH), Loxo Oncology (LOXO) and Spark Therapeutics (ONCE).
Who are Sarepta Therapeutics' key executives?
Sarepta Therapeutics' management team includes the folowing people:
- Douglas S. Ingram, President, Chief Executive Officer
- Sandesh Mahatme, Executive Vice President, Chief Financial Officer and Chief Business Officer
- David Tyronne Howton Jr., Senior Vice President, General Counsel, Corporate Secretary
- Alexander Cumbo, Senior Vice President, Global Commercial Development
- Shamim Ruff, Senior Vice President - Regulatory Affairs and Quality
- Catherine Stehman-Breen M.D., Senior Vice President, Chief Medical Officer
- Richard J. Barry, Independent Director
- M. Kathleen Behrens Ph.D., Independent Director
- Claude Nicaise M.D., Independent Director
- Hans Wigzell M.D., Ph.D., Independent Director
How do I buy Sarepta Therapeutics stock?
Shares of Sarepta Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Sarepta Therapeutics' stock price today?
MarketBeat Community Rating for Sarepta Therapeutics (NASDAQ AVII)MarketBeat's community ratings are surveys of what our community members think about Sarepta Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Sarepta Therapeutics stock can currently be purchased for approximately $0.66.
Consensus Ratings for Sarepta Therapeutics (NASDAQ:AVII) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|Consensus Price Target History for Sarepta Therapeutics (NASDAQ:AVII)
Analysts' Ratings History for Sarepta Therapeutics (NASDAQ:AVII)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Sarepta Therapeutics (NASDAQ:AVII)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for Sarepta Therapeutics (NASDAQ:AVII)
Current Year EPS Consensus Estimate: $-0.270 EPS
Dividend History for Sarepta Therapeutics (NASDAQ:AVII)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Sarepta Therapeutics (NASDAQ:AVII)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Sarepta Therapeutics (NASDAQ:AVII)
Latest Headlines for Sarepta Therapeutics (NASDAQ:AVII)
|Sarepta Therapeutics Inc (SRPT) Stock Heads Higher on Analyst Upgrade|
investorplace.com - March 2 at 1:31 PM
|Sarepta Under Pressure As FDA Approves Marathon Pharma's Emflaza For DMD Treatment|
feeds.benzinga.com - February 9 at 3:46 PM
|Sarepta Soars Following Encouraging Exondys 51 News|
feeds.benzinga.com - January 10 at 12:48 PM
|Noteworthy Wednesday Option Activity: SRPT, DAL, C|
www.forbes.com - December 14 at 5:43 PM
|Sarepta Shares Fall After Anthem Blue Cross Finds Issue With Eteplirsen|
feeds.benzinga.com - October 7 at 12:54 PM
|Sarepta Wins Exclusive License, Collaboration Deal for European Rights To Summit's DMD Drug|
feeds.benzinga.com - October 4 at 10:21 AM
|Sarepta Dosing First Patients In Phase 3 Trial Of Duchenne Muscular Dystrophy Drug|
feeds.benzinga.com - September 29 at 8:19 AM
|Better Buy: BioMarin Pharmaceuticals Inc. vs. Sarepta Therapeutics Inc|
www.fool.com - September 28 at 1:16 PM
|3 Reasons Sarepta Shares Rallied Following News Of $225 Million Offering|
feeds.benzinga.com - September 22 at 3:49 PM
|FDA Commish Says Sarepta's DMD Study Should Be Retracted|
feeds.benzinga.com - September 22 at 10:58 AM
|Why Infoblox Inc (BLOX), Isle of Capri Casinos (ISLE) and Sarepta Therapeutics Inc (SRPT) Are 3 of Today’s Best Stocks|
investorplace.com - September 19 at 5:58 PM
|Sarepta Analysts Turn Bullish After Duchenne Muscular Dystrophy Drug Eteplirsen Gets Approval|
feeds.benzinga.com - September 19 at 3:50 PM
|Oppenheimer Weighs In on Sarepta's Eteplirsen|
feeds.benzinga.com - September 19 at 12:47 PM
|Why Monsanto Company (MON), Sarepta Therapeutics Inc (SRPT) and VF Corp (VFC) Are 3 of Today’s Worst Stocks|
investorplace.com - September 15 at 4:54 PM
|India close to signing Rafale jet deal: government official|
www.reuters.com - September 15 at 12:33 PM
|Exclusive: Dr. Ron Farkas, Eteplirsen's Harshest Critic, Has Left The FDA|
feeds.benzinga.com - September 13 at 9:48 PM
|Noteworthy Friday Option Activity: SRPT, NUS, IBM|
www.forbes.com - August 5 at 12:31 PM
|Watch These 10 Huge Put Purchases In Thursday Trade|
feeds.benzinga.com - July 28 at 3:54 AM
|Sarepta Therapeutics Inc's Stock Has Plunged 47% in 2016. Here's Why.|
www.fool.com - July 4 at 8:24 AM
|Short Interest In Sarepta Therapeutics Moves 15% Higher|
www.thestreet.com - February 27 at 2:50 PM
|Here Is Why Sarepta Therapeutics Inc Slid Today|
www.bidnessetc.com - February 9 at 2:33 PM
|Sarepta Therapeutics (SRPT) PDUFA for Eteplirsen Extended|
www.streetinsider.com - February 8 at 2:40 PM
|Covered Call Alerts For Apple, Sarepta Therapeutics, Freeport-McMoRan, PayPal Holdings Inc. and Vuzix Corporation Released By InvestorsObserver|
www.prnewswire.com - February 4 at 2:55 PM
|Sarepta Therapeutics Inc. (SRPT) Plunged To An 8-Month Low|
www.rttnews.com - January 20 at 2:23 PM
|Sarepta Therapeutics Inc. (SRPT) Is Sinking After FDA Rejects BioMarin Drug|
www.nasdaq.com - January 17 at 1:55 PM
|Sarepta Therapeutics Made Investors Millionaires in 2 Years|
www.investopedia.com - August 14 at 12:01 PM
Sarepta Therapeutics (AVII) Chart for Friday, October, 20, 2017